TXA (Tranexamic Acid) Risk Evaluation in Combat Casualties (TRECC)
Background The use of tranexamic acid (TXA) has become increasingly prevalent for hemorrhage prevention in military trauma patients due to its known survival benefits. There is concern of increased venous thromboembolism (VTE) subsequent to receiving TXA. The purpose of this retrospective study was...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-12-01
|
| Series: | Trauma Surgery & Acute Care Open |
| Online Access: | https://tsaco.bmj.com/content/5/1/e000353.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850199721116696576 |
|---|---|
| author | Kathleen E Adair Joshua D Patrick Eric J Kliber Matthew N Peterson Seth R Holland |
| author_facet | Kathleen E Adair Joshua D Patrick Eric J Kliber Matthew N Peterson Seth R Holland |
| author_sort | Kathleen E Adair |
| collection | DOAJ |
| description | Background The use of tranexamic acid (TXA) has become increasingly prevalent for hemorrhage prevention in military trauma patients due to its known survival benefits. There is concern of increased venous thromboembolism (VTE) subsequent to receiving TXA. The purpose of this retrospective study was to determine the rate of VTE in severely injured military personnel during Operation Enduring Freedom (2009–2014).Methods An analysis of 859 military trauma patients from the 2009–2014 Department of Defense Trauma Registry included subjects with an injury severity score (ISS) >10 and a massive transfusion (MT) (>10 units of blood products in the first 24 hours). Outcomes included a documented VTE (eg, deep vein thrombosis (DVT) or pulmonary embolism (PE)) during the patient’s hospital course. Comparison between those who did/did not receive TXA was analyzed using three separate multiple regression analyses using listwise deletion, systematic replacement and multiple imputation.Results Subjects (n=620) met inclusion criteria with 27% (n=169) having a documented VTE. A total of 30% that received TXA had a documented VTE, 26% that did not receive TXA had a documented VTE and 43% (n=264, n=620) of the sample did not have TXA documented as either given or not given. Multiple regression analyses using listwise deletion and systematic replacement of the TXA variable demonstrated no difference in odds of VTE, whereas the multiple imputation analysis demonstrated a 3% increased odds of VTE, a9.4% increased odds of PE and 8.1% decreased odds of DVT with TXA administration.Discussion TXA use with an ISS >10 and MT resuscitation had a 3% increased odds of VTE and an increased odds of PE, whereas the odds of DVT were found to be decreased after multiple imputation analysis. Further research on the long-term risks and benefits of TXA usage in the military population is recommended.Level of evidence IV—therapeutic. |
| format | Article |
| id | doaj-art-4b358a5e428f4749bdceaab5d2838d5c |
| institution | OA Journals |
| issn | 2397-5776 |
| language | English |
| publishDate | 2020-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Trauma Surgery & Acute Care Open |
| spelling | doaj-art-4b358a5e428f4749bdceaab5d2838d5c2025-08-20T02:12:33ZengBMJ Publishing GroupTrauma Surgery & Acute Care Open2397-57762020-12-015110.1136/tsaco-2019-000353TXA (Tranexamic Acid) Risk Evaluation in Combat Casualties (TRECC)Kathleen E Adair0Joshua D Patrick1Eric J Kliber2Matthew N Peterson3Seth R Holland41 HHPR, Baylor University, Waco, Texas, USA2 Statistical Science, Baylor University, Waco, Texas, USA3 San Antonio Military Medical Center, Fort Sam Houston, Texas, USA1 HHPR, Baylor University, Waco, Texas, USA3 San Antonio Military Medical Center, Fort Sam Houston, Texas, USABackground The use of tranexamic acid (TXA) has become increasingly prevalent for hemorrhage prevention in military trauma patients due to its known survival benefits. There is concern of increased venous thromboembolism (VTE) subsequent to receiving TXA. The purpose of this retrospective study was to determine the rate of VTE in severely injured military personnel during Operation Enduring Freedom (2009–2014).Methods An analysis of 859 military trauma patients from the 2009–2014 Department of Defense Trauma Registry included subjects with an injury severity score (ISS) >10 and a massive transfusion (MT) (>10 units of blood products in the first 24 hours). Outcomes included a documented VTE (eg, deep vein thrombosis (DVT) or pulmonary embolism (PE)) during the patient’s hospital course. Comparison between those who did/did not receive TXA was analyzed using three separate multiple regression analyses using listwise deletion, systematic replacement and multiple imputation.Results Subjects (n=620) met inclusion criteria with 27% (n=169) having a documented VTE. A total of 30% that received TXA had a documented VTE, 26% that did not receive TXA had a documented VTE and 43% (n=264, n=620) of the sample did not have TXA documented as either given or not given. Multiple regression analyses using listwise deletion and systematic replacement of the TXA variable demonstrated no difference in odds of VTE, whereas the multiple imputation analysis demonstrated a 3% increased odds of VTE, a9.4% increased odds of PE and 8.1% decreased odds of DVT with TXA administration.Discussion TXA use with an ISS >10 and MT resuscitation had a 3% increased odds of VTE and an increased odds of PE, whereas the odds of DVT were found to be decreased after multiple imputation analysis. Further research on the long-term risks and benefits of TXA usage in the military population is recommended.Level of evidence IV—therapeutic.https://tsaco.bmj.com/content/5/1/e000353.full |
| spellingShingle | Kathleen E Adair Joshua D Patrick Eric J Kliber Matthew N Peterson Seth R Holland TXA (Tranexamic Acid) Risk Evaluation in Combat Casualties (TRECC) Trauma Surgery & Acute Care Open |
| title | TXA (Tranexamic Acid) Risk Evaluation in Combat Casualties (TRECC) |
| title_full | TXA (Tranexamic Acid) Risk Evaluation in Combat Casualties (TRECC) |
| title_fullStr | TXA (Tranexamic Acid) Risk Evaluation in Combat Casualties (TRECC) |
| title_full_unstemmed | TXA (Tranexamic Acid) Risk Evaluation in Combat Casualties (TRECC) |
| title_short | TXA (Tranexamic Acid) Risk Evaluation in Combat Casualties (TRECC) |
| title_sort | txa tranexamic acid risk evaluation in combat casualties trecc |
| url | https://tsaco.bmj.com/content/5/1/e000353.full |
| work_keys_str_mv | AT kathleeneadair txatranexamicacidriskevaluationincombatcasualtiestrecc AT joshuadpatrick txatranexamicacidriskevaluationincombatcasualtiestrecc AT ericjkliber txatranexamicacidriskevaluationincombatcasualtiestrecc AT matthewnpeterson txatranexamicacidriskevaluationincombatcasualtiestrecc AT sethrholland txatranexamicacidriskevaluationincombatcasualtiestrecc |